Qiagen N.v. Stock
€38.50
Your prediction
Financial data and news for Qiagen N.v.
sharewise wants to provide you with the best news and tools for Qiagen N.v., so we directly link to the best financial data sources.
Financials
News
EQS-Adhoc: QIAGEN N.V.: QIAGEN announces CEO transition plan
EQS-Adhoc: QIAGEN N.V.: QIAGEN to return approximately $500 million to shareholders through a synthetic share repurchase
EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. launches non-US offering of net share settled convertible bonds
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free
QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the EZ2 DNA Investigator Sep&Prep Kit, a fully automated solution for processing sexual assault samples, at the
QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the 4,000th placement of its QIAcube Connect instrument, a significant milestone in driving automation adoption for sample
QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date / time: Tuesday, November 4, shortly after 22:
QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has achieved CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an
QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled
QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR
QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR
QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced solid results for Q2 2025 that exceeded the outlook, and increased the full-year 2025 outlook for net sales growth while
QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing
QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2025.
Press release date / time: Tuesday, August 5, shortly after 22:0
QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive